SNOAMEDIUM SIGNALFINANCIAL10-K

SNOA showed meaningful improvement in operating cash flow and reduced losses while growing revenue modestly, though a dramatic reduction in outstanding shares suggests significant corporate restructuring activity.

The company's operating cash flow improved substantially from -$2.4M to -$88K, indicating better working capital management and operational efficiency. However, the reduction in outstanding shares from 18.8 million to 1.6 million shares represents a major corporate action that likely diluted existing shareholders or involved significant restructuring that investors should investigate further.

Comparing 2025-06-17 vs 2024-06-17View on EDGAR →
FINANCIAL ANALYSIS

SNOA demonstrated encouraging operational progress with revenue growing 12.2% to $14.3M and gross profit expanding 15.2% to $5.5M, while net losses narrowed meaningfully from -$4.8M to -$3.5M. Cash position strengthened notably from $3.1M to $5.4M, complemented by the dramatic improvement in operating cash flow. The overall financial picture suggests improving operational performance, though the massive share count reduction and declining stockholders' equity indicate significant corporate restructuring that overshadows the operational improvements.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+96.3%
-$2.4M-$88K

Operating cash flow surged 96.3% — exceptional cash generation, highest quality earnings signal.

Cash & Equivalents
Balance Sheet
+71.8%
$3.1M$5.4M

Cash position surged 71.8% — strong cash generation or capital raise providing significant financial cushion.

Net Income
P&L
+28.5%
-$4.8M-$3.5M

Net income grew 28.5% — bottom-line growth signals improving overall business health.

Stockholders Equity
Balance Sheet
-28.1%
$6.1M$4.4M

Equity decreased 28.1% — buybacks or losses reducing book value, monitor solvency ratios.

Total Debt
Balance Sheet
+27.5%
$262K$334K

Debt rose 27.5% — additional borrowing for investment or operations; monitor coverage ratios.

Interest Expense
P&L
-25%
$16K$12K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Accounts Receivable
Balance Sheet
-23%
$2.9M$2.2M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Operating Income
P&L
+21.1%
-$4.7M-$3.7M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Gross Profit
P&L
+15.2%
$4.7M$5.5M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+12.2%
$12.7M$14.3M

Revenue growing 12.2% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2025-06-17
PRIOR — 2024-06-17
ADDED
There were 1,642,765 shares of the registrant s common stock issued and outstanding on June 16, 2025.
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 3 8 ITEM 6.
Management s Discussion and Analysis of Financial Condition and Results of Operations 3 8 ITEM 7A.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 4 8 ITEM 13.
Form 10-K Summary 52 Signatures 53 i PART I This report includes forward-looking statements.
+7 more — sign up free →
REMOVED
There were 18,773,635 shares of the registrant s common stock issued and outstanding on June 17, 2024.
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 37 ITEM 6.
Management s Discussion and Analysis of Financial Condition and Results of Operations 38 ITEM 7A.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 47 ITEM 13.
Form 10-K Summary 50 Signatures 51 i PART I This report includes forward-looking statements.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →